Transmedics Group

TransMedics is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company developed the Organ Care System ("OCS") to replace a decades-old standard of care. The OCS represents a paradigm shift that transforms organ preservation for transplantation from a static state to a dynamic environment that enables new capabilities, including organ optimization and assessment. The company's OCS technology replicates many aspects of the organ's natural living and functioning environment outside of the human body.
  • TickerTMDX
  • ISINUS89377M1099
  • ExchangeNASDAQ Stock Market
  • SectorHealth Care Equipment & Services
  • CountryUnited States
 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics Announces Temporary Postponement of OCS Heart FDA Advisory...

TransMedics Announces Temporary Postponement of OCS Heart FDA Advisory Panel Committee Meeting ANDOVER, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that the FDA has temporarily postponed the Advisory Committee meeting to review TransMedics’ premarket approval application for its OCS Heart. The postponement of the meeting, which was-previously scheduled for October 7th, 2020 will allow the...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics to Present at the 18th Annual Morgan Stanley Global Health...

TransMedics to Present at the 18th Annual Morgan Stanley Global Healthcare Conference ANDOVER, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of management will be virtually participating in a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference. The fireside chat will take place on Thursday, September 17, 2020 at 8:00 a.m. EDT. Event: Morgan Stanley Glo...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics Reports Second Quarter 2020 Financial Results

TransMedics Reports Second Quarter 2020 Financial Results ANDOVER, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended June 30, 2020. Recent Highlights OCS Heart FDA Advisory Committee meeting rescheduled as a virtual meeting to be held on October 7, 2020Submitted OCS Liver PMA to FDA in June 2020OCS Heart DCD U.S. clinical program surpassed 50 transplants;...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics to Present at the Canaccord 40th Annual Growth Conference

TransMedics to Present at the Canaccord 40th Annual Growth Conference ANDOVER, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of management will be presenting at the virtual Canaccord 40th Annual Growth Conference. The presentation will take place on Thursday, August 13, 2020 at 10:00 a.m. EDT. Event: Canaccord 40th Annual Growth ConferenceDate: Thursday, August 13, 2020Time: 10...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics to Report Second Quarter 2020 Financial Results on August ...

TransMedics to Report Second Quarter 2020 Financial Results on August 5, 2020 ANDOVER, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter after market close on Wednesday, August 5, 2020. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics Announces Temporary Postponement of OCS Heart FDA Advisory...

TransMedics Announces Temporary Postponement of OCS Heart FDA Advisory Panel Committee Meeting ANDOVER, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that the FDA has temporarily postponed the Advisory Committee meeting to review TransMedics’ premarket approval application for its OCS Heart. The postponement of the meeting, which was-previously scheduled for October 7th, 2020 will allow the...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics to Present at the 18th Annual Morgan Stanley Global Health...

TransMedics to Present at the 18th Annual Morgan Stanley Global Healthcare Conference ANDOVER, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of management will be virtually participating in a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference. The fireside chat will take place on Thursday, September 17, 2020 at 8:00 a.m. EDT. Event: Morgan Stanley Glo...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics Reports Second Quarter 2020 Financial Results

TransMedics Reports Second Quarter 2020 Financial Results ANDOVER, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended June 30, 2020. Recent Highlights OCS Heart FDA Advisory Committee meeting rescheduled as a virtual meeting to be held on October 7, 2020Submitted OCS Liver PMA to FDA in June 2020OCS Heart DCD U.S. clinical program surpassed 50 transplants;...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics to Present at the Canaccord 40th Annual Growth Conference

TransMedics to Present at the Canaccord 40th Annual Growth Conference ANDOVER, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of management will be presenting at the virtual Canaccord 40th Annual Growth Conference. The presentation will take place on Thursday, August 13, 2020 at 10:00 a.m. EDT. Event: Canaccord 40th Annual Growth ConferenceDate: Thursday, August 13, 2020Time: 10...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics to Report Second Quarter 2020 Financial Results on August ...

TransMedics to Report Second Quarter 2020 Financial Results on August 5, 2020 ANDOVER, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter after market close on Wednesday, August 5, 2020. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics Announces Temporary Postponement of OCS Heart FDA Advisory...

TransMedics Announces Temporary Postponement of OCS Heart FDA Advisory Panel Committee Meeting ANDOVER, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that the FDA has temporarily postponed the Advisory Committee meeting to review TransMedics’ premarket approval application for its OCS Heart. The postponement of the meeting, which was-previously scheduled for October 7th, 2020 will allow the...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics to Present at the 18th Annual Morgan Stanley Global Health...

TransMedics to Present at the 18th Annual Morgan Stanley Global Healthcare Conference ANDOVER, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of management will be virtually participating in a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference. The fireside chat will take place on Thursday, September 17, 2020 at 8:00 a.m. EDT. Event: Morgan Stanley Glo...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics Reports Second Quarter 2020 Financial Results

TransMedics Reports Second Quarter 2020 Financial Results ANDOVER, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended June 30, 2020. Recent Highlights OCS Heart FDA Advisory Committee meeting rescheduled as a virtual meeting to be held on October 7, 2020Submitted OCS Liver PMA to FDA in June 2020OCS Heart DCD U.S. clinical program surpassed 50 transplants;...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics to Present at the Canaccord 40th Annual Growth Conference

TransMedics to Present at the Canaccord 40th Annual Growth Conference ANDOVER, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of management will be presenting at the virtual Canaccord 40th Annual Growth Conference. The presentation will take place on Thursday, August 13, 2020 at 10:00 a.m. EDT. Event: Canaccord 40th Annual Growth ConferenceDate: Thursday, August 13, 2020Time: 10...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics to Report Second Quarter 2020 Financial Results on August ...

TransMedics to Report Second Quarter 2020 Financial Results on August 5, 2020 ANDOVER, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter after market close on Wednesday, August 5, 2020. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics Announces Temporary Postponement of OCS Heart FDA Advisory...

TransMedics Announces Temporary Postponement of OCS Heart FDA Advisory Panel Committee Meeting ANDOVER, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that the FDA has temporarily postponed the Advisory Committee meeting to review TransMedics’ premarket approval application for its OCS Heart. The postponement of the meeting, which was-previously scheduled for October 7th, 2020 will allow the...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics to Present at the 18th Annual Morgan Stanley Global Health...

TransMedics to Present at the 18th Annual Morgan Stanley Global Healthcare Conference ANDOVER, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of management will be virtually participating in a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference. The fireside chat will take place on Thursday, September 17, 2020 at 8:00 a.m. EDT. Event: Morgan Stanley Glo...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics Reports Second Quarter 2020 Financial Results

TransMedics Reports Second Quarter 2020 Financial Results ANDOVER, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended June 30, 2020. Recent Highlights OCS Heart FDA Advisory Committee meeting rescheduled as a virtual meeting to be held on October 7, 2020Submitted OCS Liver PMA to FDA in June 2020OCS Heart DCD U.S. clinical program surpassed 50 transplants;...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics to Present at the Canaccord 40th Annual Growth Conference

TransMedics to Present at the Canaccord 40th Annual Growth Conference ANDOVER, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of management will be presenting at the virtual Canaccord 40th Annual Growth Conference. The presentation will take place on Thursday, August 13, 2020 at 10:00 a.m. EDT. Event: Canaccord 40th Annual Growth ConferenceDate: Thursday, August 13, 2020Time: 10...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics to Report Second Quarter 2020 Financial Results on August ...

TransMedics to Report Second Quarter 2020 Financial Results on August 5, 2020 ANDOVER, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter after market close on Wednesday, August 5, 2020. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics Announces Temporary Postponement of OCS Heart FDA Advisory...

TransMedics Announces Temporary Postponement of OCS Heart FDA Advisory Panel Committee Meeting ANDOVER, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that the FDA has temporarily postponed the Advisory Committee meeting to review TransMedics’ premarket approval application for its OCS Heart. The postponement of the meeting, which was-previously scheduled for October 7th, 2020 will allow the...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics to Present at the 18th Annual Morgan Stanley Global Health...

TransMedics to Present at the 18th Annual Morgan Stanley Global Healthcare Conference ANDOVER, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of management will be virtually participating in a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference. The fireside chat will take place on Thursday, September 17, 2020 at 8:00 a.m. EDT. Event: Morgan Stanley Glo...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics Reports Second Quarter 2020 Financial Results

TransMedics Reports Second Quarter 2020 Financial Results ANDOVER, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended June 30, 2020. Recent Highlights OCS Heart FDA Advisory Committee meeting rescheduled as a virtual meeting to be held on October 7, 2020Submitted OCS Liver PMA to FDA in June 2020OCS Heart DCD U.S. clinical program surpassed 50 transplants;...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics to Present at the Canaccord 40th Annual Growth Conference

TransMedics to Present at the Canaccord 40th Annual Growth Conference ANDOVER, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of management will be presenting at the virtual Canaccord 40th Annual Growth Conference. The presentation will take place on Thursday, August 13, 2020 at 10:00 a.m. EDT. Event: Canaccord 40th Annual Growth ConferenceDate: Thursday, August 13, 2020Time: 10...

 PRESS RELEASE
TMDX Transmedics Gro... (Health Care)

TransMedics to Report Second Quarter 2020 Financial Results on August ...

TransMedics to Report Second Quarter 2020 Financial Results on August 5, 2020 ANDOVER, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter after market close on Wednesday, August 5, 2020. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch